Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJMBR (2) Autor Moreira,J.N. (2) Gaspar,R. (1) Pedroso de Lima,M.C. (1) Pereira,J.P. (1) Santos,A.O. (1) Simões,S. (1) Mais... Palavra-chave Antagonist G (1) Antisense ODN (1) Bcl-2 (1) Chemosensitization (1) Doxorubicin (1) Flow cytometry (1) Gene silencing (1) Lung cancer (1) Pegylated liposomes (1) SiRNA (1) Small cell lung cancer (1) Targeting (1) Mais... Tipo do documento Info:eu-repo/semantics/article (2) Ano 2010 (1) 2004 (1) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última Antagonist G-mediated targeting and cytotoxicity of liposomal doxorubicin in NCI-H82 variant small cell lung cancer BJMBR Moreira,J.N.; Gaspar,R.. The aim of the present study was to characterize the interactions of antagonist G (H-Arg-D-Trp-NmePhe-D-Trp-Leu-Met-NH 2)-targeted sterically stabilized liposomes with the human variant small cell lung cancer (SCLC) H82 cell line and to evaluate the antiproliferative activity of encapsulated doxorubicin against this cell line. Variant SCLC tumors are known to be more resistant to chemotherapy than classic SCLC tumors. The cellular association of antagonist G-targeted (radiolabeled) liposomes was 20-30-fold higher than that of non-targeted liposomes. Our data suggest that a maximum of 12,000 antagonist G-targeted liposomes were internalized/cell during 1-h incubation at 37ºC. Confocal microscopy experiments using pyranine-containing liposomes further... Tipo: Info:eu-repo/semantics/article Palavras-chave: Pegylated liposomes; Doxorubicin; Targeting; Antagonist G; Lung cancer. Ano: 2004 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2004000800008 In vitro modulation of Bcl-2 levels in small cell lung cancer cells: effects on cell viability BJMBR Santos,A.O.; Pereira,J.P.; Pedroso de Lima,M.C.; Simões,S.; Moreira,J.N.. Small cell lung cancer (SCLC) is an aggressive disease, representing 15% of all cases of lung cancer, has high metastatic potential and low prognosis that urgently demands the development of novel therapeutic approaches. One of the proposed approaches has been the down-regulation of BCL2, with poorly clarified and controversial therapeutic value regarding SCLC. The use of anti-BCL2 small interfering RNA (siRNA) in SCLC has never been reported. The aim of the present study was to select and test the in vitro efficacy of anti-BCL2 siRNA sequences against the protein and mRNA levels of SCLC cells, and their effects on cytotoxicity and chemosensitization. Two anti-BCL2 siRNAs and the anti-BCL2 G3139 oligodeoxynucleotide (ODN) were evaluated in SCLC cells by... Tipo: Info:eu-repo/semantics/article Palavras-chave: Small cell lung cancer; Gene silencing; Bcl-2; SiRNA; Antisense ODN; Flow cytometry; Chemosensitization. Ano: 2010 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2010001000013 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco